Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 56 | 2023 | 109 | 10.630 |
Why?
|
| Graft vs Host Disease | 23 | 2023 | 54 | 4.120 |
Why?
|
| Leukemia, Myeloid, Acute | 16 | 2023 | 51 | 2.800 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2023 | 36 | 1.610 |
Why?
|
| Transplantation Conditioning | 23 | 2023 | 39 | 1.380 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2022 | 33 | 0.910 |
Why?
|
| Transplantation, Homologous | 17 | 2023 | 278 | 0.890 |
Why?
|
| Hodgkin Disease | 5 | 2021 | 19 | 0.880 |
Why?
|
| Hematologic Neoplasms | 2 | 2020 | 17 | 0.800 |
Why?
|
| Humans | 68 | 2023 | 27072 | 0.790 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2023 | 13 | 0.750 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 36 | 0.680 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2021 | 245 | 0.660 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 206 | 0.650 |
Why?
|
| Recurrence | 13 | 2023 | 310 | 0.640 |
Why?
|
| Eye Diseases | 4 | 2019 | 7 | 0.620 |
Why?
|
| Primary Myelofibrosis | 3 | 2023 | 3 | 0.600 |
Why?
|
| Retrospective Studies | 25 | 2023 | 3538 | 0.600 |
Why?
|
| Cyclophosphamide | 8 | 2023 | 48 | 0.510 |
Why?
|
| Middle Aged | 27 | 2023 | 8923 | 0.510 |
Why?
|
| Adult | 27 | 2023 | 7831 | 0.500 |
Why?
|
| Salvage Therapy | 3 | 2021 | 35 | 0.490 |
Why?
|
| Transplantation, Autologous | 9 | 2022 | 161 | 0.480 |
Why?
|
| Prognosis | 12 | 2023 | 785 | 0.410 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 69 | 0.400 |
Why?
|
| Disease-Free Survival | 10 | 2022 | 174 | 0.390 |
Why?
|
| Multiple Myeloma | 2 | 2022 | 19 | 0.380 |
Why?
|
| Calcineurin Inhibitors | 5 | 2023 | 16 | 0.370 |
Why?
|
| Adolescent | 12 | 2023 | 2172 | 0.360 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 16 | 0.350 |
Why?
|
| Male | 23 | 2022 | 14772 | 0.340 |
Why?
|
| Aged | 20 | 2023 | 8997 | 0.340 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2020 | 8 | 0.320 |
Why?
|
| Young Adult | 12 | 2021 | 1994 | 0.320 |
Why?
|
| Allografts | 5 | 2021 | 214 | 0.300 |
Why?
|
| Female | 22 | 2023 | 15212 | 0.290 |
Why?
|
| Survival Rate | 8 | 2021 | 342 | 0.270 |
Why?
|
| Hemoglobin SC Disease | 1 | 2006 | 1 | 0.260 |
Why?
|
| Splenic Diseases | 1 | 2006 | 2 | 0.260 |
Why?
|
| Rituximab | 3 | 2023 | 48 | 0.250 |
Why?
|
| Chromosome Aberrations | 3 | 2021 | 17 | 0.250 |
Why?
|
| Melphalan | 5 | 2023 | 6 | 0.230 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 120 | 0.230 |
Why?
|
| Mycoses | 1 | 2023 | 21 | 0.210 |
Why?
|
| Risk Factors | 5 | 2023 | 2302 | 0.210 |
Why?
|
| Scedosporium | 1 | 2023 | 4 | 0.210 |
Why?
|
| Quality of Life | 4 | 2022 | 629 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2023 | 51 | 0.210 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2023 | 2 | 0.210 |
Why?
|
| Myeloablative Agonists | 2 | 2020 | 2 | 0.200 |
Why?
|
| POEMS Syndrome | 1 | 2022 | 1 | 0.200 |
Why?
|
| Remission Induction | 5 | 2022 | 90 | 0.200 |
Why?
|
| Unrelated Donors | 4 | 2023 | 5 | 0.190 |
Why?
|
| Vidarabine | 4 | 2023 | 9 | 0.190 |
Why?
|
| Drug Resistance | 2 | 2019 | 47 | 0.190 |
Why?
|
| Autografts | 2 | 2019 | 31 | 0.190 |
Why?
|
| Bone Marrow | 4 | 2023 | 76 | 0.190 |
Why?
|
| Heart Failure | 1 | 2023 | 151 | 0.190 |
Why?
|
| Hypogonadism | 1 | 2021 | 7 | 0.190 |
Why?
|
| Infertility | 1 | 2021 | 8 | 0.190 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 20 | 0.190 |
Why?
|
| Busulfan | 4 | 2023 | 4 | 0.190 |
Why?
|
| Bone Marrow Transplantation | 4 | 2023 | 22 | 0.180 |
Why?
|
| Cytomegalovirus | 1 | 2021 | 15 | 0.180 |
Why?
|
| Roseolovirus Infections | 1 | 2021 | 4 | 0.180 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2021 | 6 | 0.180 |
Why?
|
| Siblings | 4 | 2022 | 15 | 0.180 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 18 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2021 | 35 | 0.180 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 42 | 0.180 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2020 | 2 | 0.180 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2020 | 10 | 0.180 |
Why?
|
| Return to Work | 1 | 2021 | 65 | 0.170 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 4 | 0.170 |
Why?
|
| Calcineurin | 1 | 2020 | 9 | 0.170 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 2 | 0.170 |
Why?
|
| Infliximab | 1 | 2020 | 17 | 0.170 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 321 | 0.170 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2019 | 3 | 0.170 |
Why?
|
| Transplantation, Haploidentical | 1 | 2019 | 1 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2021 | 257 | 0.160 |
Why?
|
| Steroids | 1 | 2019 | 23 | 0.160 |
Why?
|
| Typhlitis | 1 | 2019 | 2 | 0.160 |
Why?
|
| Mucositis | 1 | 2019 | 5 | 0.160 |
Why?
|
| Neoplasms | 1 | 2022 | 237 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 189 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 5 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2019 | 24 | 0.150 |
Why?
|
| Lung Diseases | 1 | 2019 | 45 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 86 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 90 | 0.150 |
Why?
|
| Acute Disease | 3 | 2023 | 176 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 236 | 0.150 |
Why?
|
| Incidence | 4 | 2023 | 759 | 0.150 |
Why?
|
| Lymphoma | 1 | 2017 | 35 | 0.140 |
Why?
|
| Lymphoma, B-Cell | 1 | 2017 | 10 | 0.140 |
Why?
|
| Cachexia | 1 | 2017 | 12 | 0.140 |
Why?
|
| Child, Preschool | 3 | 2023 | 641 | 0.120 |
Why?
|
| Chronic Disease | 3 | 2023 | 415 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 595 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2020 | 3485 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4777 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 1792 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 2012 | 22 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 46 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2021 | 624 | 0.100 |
Why?
|
| Melanoma | 1 | 2012 | 60 | 0.100 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 78 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2022 | 1890 | 0.090 |
Why?
|
| Vincristine | 2 | 2023 | 23 | 0.090 |
Why?
|
| Tacrolimus | 2 | 2021 | 15 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 198 | 0.090 |
Why?
|
| Prednisone | 2 | 2023 | 66 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2023 | 57 | 0.090 |
Why?
|
| Leukocyte Count | 2 | 2020 | 61 | 0.080 |
Why?
|
| Mutation | 2 | 2023 | 348 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 175 | 0.080 |
Why?
|
| Treatment Failure | 2 | 2020 | 158 | 0.080 |
Why?
|
| Cytarabine | 2 | 2020 | 11 | 0.080 |
Why?
|
| Etoposide | 2 | 2020 | 27 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2020 | 1778 | 0.070 |
Why?
|
| Registries | 2 | 2020 | 189 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 329 | 0.070 |
Why?
|
| Comorbidity | 2 | 2020 | 481 | 0.070 |
Why?
|
| Pain | 2 | 2021 | 413 | 0.070 |
Why?
|
| Disease Progression | 2 | 2022 | 673 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 347 | 0.070 |
Why?
|
| Child | 2 | 2021 | 1295 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Splenomegaly | 1 | 2006 | 6 | 0.060 |
Why?
|
| United States | 2 | 2023 | 2035 | 0.060 |
Why?
|
| Splenectomy | 1 | 2006 | 6 | 0.060 |
Why?
|
| Abdominal Pain | 1 | 2006 | 7 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 54 | 0.060 |
Why?
|
| Fever | 1 | 2006 | 34 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 363 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 23 | 0.050 |
Why?
|
| Toes | 1 | 2023 | 6 | 0.050 |
Why?
|
| Voriconazole | 1 | 2023 | 12 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2023 | 43 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2023 | 79 | 0.050 |
Why?
|
| Whole-Body Irradiation | 1 | 2022 | 9 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2022 | 22 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2022 | 13 | 0.050 |
Why?
|
| Bortezomib | 1 | 2021 | 3 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 7 | 0.050 |
Why?
|
| Survivors | 1 | 2021 | 70 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 47 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2020 | 12 | 0.040 |
Why?
|
| Cell Count | 1 | 2020 | 81 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2020 | 1 | 0.040 |
Why?
|
| Carmustine | 1 | 2020 | 2 | 0.040 |
Why?
|
| Pyrazines | 1 | 2019 | 11 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2020 | 47 | 0.040 |
Why?
|
| Aniline Compounds | 1 | 2019 | 35 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 60 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2020 | 58 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 51 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 53 | 0.040 |
Why?
|
| Blood Donors | 1 | 2019 | 5 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 14 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 74 | 0.040 |
Why?
|
| Alemtuzumab | 1 | 2018 | 4 | 0.040 |
Why?
|
| Europe | 1 | 2018 | 58 | 0.040 |
Why?
|
| Age Factors | 1 | 2020 | 766 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2018 | 121 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2017 | 3 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2017 | 16 | 0.030 |
Why?
|
| Ifosfamide | 1 | 2017 | 14 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 21 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 119 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 167 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 30 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2017 | 34 | 0.030 |
Why?
|
| Methotrexate | 1 | 2017 | 38 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 272 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 562 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 127 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 333 | 0.020 |
Why?
|